With Cellares preparing to begin…
With Cellares preparing to begin commercial-stage production in 2027, the [...]
CalciMedica’s stock nosedived…
CalciMedica’s stock nosedived after the biotech abandoned a phase 2 [...]
Boehringer Ingelheim has shared…
Boehringer Ingelheim has shared more phase 2 data on its [...]
Nearly two decades after the…
Nearly two decades after the parties first floated the idea [...]
China’s National Medical…
China’s National Medical Products Administration suspended the import, sale and [...]
The FDA is freeing Intellia’s…
The FDA is freeing Intellia’s CRISPR therapy from one of [...]
Ahead of its acquisition by cancer…
Ahead of its acquisition by cancer imaging company Kuva Labs, [...]
After posting 16.2% revenue growth…
After posting 16.2% revenue growth in the last financial year, [...]
Four years after listing on the…
Four years after listing on the Nasdaq, Genenta Sciences is [...]
The companies had committed to a…
The companies had committed to a five-year partnership in July [...]